51 articles - From Friday Nov 18 2022 to Friday Nov 25 2022
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
| Clin J Am Soc Nephrol |
| Kidney Int |
Executive Summary of the KDIGO 2022 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. As a result, the Work Group performed a comprehensive review and revised the 2018 guidance. This Executive Summary highlights key aspects of the updated guideline recommendations for 3 chapters: Chapter 2: Treatment of HCV infection in patients with CKD; Chapter 4: Management of HCV-infected patients before and after kidney transplantation; and Chapter 5: Diagnosis and management of kidney diseases associated with HCV infection. |
meta-analyses and systematic reviews
| Am J Kidney Dis |
Cardiac and Kidney Adverse Effects of HIF Prolyl-Hydroxylase Inhibitors for Anemia in Patients With CKD Not Receiving Dialysis: A Systematic Review and Meta-analysis. The occurrence of cardiac or kidney-related adverse events in the HIF-PHI groups were not different compared with placebo or ESA groups. Registration Registered at PROSPERO with record number CRD42021228243. |
| Clin J Am Soc Nephrol |
RCT, clinical trials, retrospective studies, etc…
| Am J Kidney Dis |
Antimicrobial Photodynamic Therapy in the Nasal Decolonization of Maintenance Hemodialysis Patients: A Pilot Randomized Trial. Photodynamic therapy is a feasible approach to treating nasal carriage of Staphylococcus aureus. Future larger studies should be conducted to determine if photodynamic therapy is equivalent to the standard of care with mupirocin. |
Heart Failure-Type Symptom Score Trajectories in CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. Distinct HF-type symptom burden trajectories were identified in the setting of CKD, corresponding to different baseline characteristics. These results highlight the diversity of HF-type symptom experiences in individuals with CKD. |
Improving Clinical Care for Children With CKD: A Report From a National Kidney Foundation Scientific Workshop. The key clinical recommendations pertained to five broad topics: Addressing the Needs of Patients and Parents/Caregivers; Modifying the Progression of CKD; Clinical Management of CKD-Mineral Bone Disorder and Growth Retardation; Clinical Management of Anemia, Cardiovascular Disease and Hypertension; and Transition and Transfer of Pediatric Patients to Adult Nephrology Care. This report describes the recommendations generated by the participants who attended the workshop. |
| Clin J Am Soc Nephrol |
Associations of COVID-19 Outcomes with Dialysis Modalities and Settings. In contrast, exposure to skilled nursing facilities was associated with 570%-1140% higher odds of al events during spring of 2020, although excess risk attenuated as the pandemic transpired, especially among patients who received hemodialysis in skilled nursing facilities. In conclusion, home dialysis was associated with lower risks of COVID-19 diagnosis, hospitalization, and death until vaccines were available, whereas care in skilled nursing facilities was associated with higher risks. |
Effects of Bardoxolone Methyl in Alport Syndrome. In adolescent and adult patients with Alport syndrome receiving standard of care, treatment with bardoxolone methyl resulted in preservation in eGFR relative to placebo after a 2-year study period; off-treatment results using al available data were not significantly different. Clinical trial registry name and registration number A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome - CARDINAL (CARDINAL), NCT03019185. |
Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes. Treatment with the combination of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and SGLT2 inhibitor in patients with albuminuric CKD without diabetes is expected to substantially increase kidney failure-free survival. Clinical trial registry name and registration number Benazepril for Advanced Chronic Renal Insufficiency, NCT00270426, and a Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease (Dapa-CKD), NCT03036150. |
Overview of the Medical Management of the Critically Ill Patient. These concepts are universally applicable to patients seen by nephrologists in the intensive care unit and may have particular relevance for patients with kidney failure either on dialysis or after kidney transplant. In this article, we will briefly summarize some known organ-based consequences associated with critical illness, review the components of the ABCDEF bundle (the conceptual framework for Intensive Care Unit Liberation), highlight the role nephrologists can play in implementing and complying with the ABCDEF bundle, and briefly discuss areas for additional research. |
| J Am Soc Nephrol |
Changes in Glomerular Volume, Sclerosis, and Ischemia at 5 Years after Kidney Transplantation: Incidence and Correlation with Late Graft Failure. Glomerular changes reflect important pathologic processes that predict graft loss. Measuring glomerular changes quantitatively on surveillance biopsies, especially the proportion of ischemic-appearing glomeruli, may enhance the current Banff system and be a useful surrogate end point for clinical intervention trials. |
Treatment Effect of the SGLT2 Inhibitor Empagliflozin on Chronic Syndrome of Inappropriate Antidiuresis: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. The SGLT2 inhibitor empagliflozin is a promising new treatment option for chronic SIAD-induced hyponatremia, possibly improving neurocognitive function. Larger studies are needed to confirm the observed treatment effects. Clinical trial registration |
| Kidney Int |
Immune cell heterogeneity in a mouse model of diabetic kidney disease. In this issue, Fu et al use a flow sorting strategy to generate a very large immune cell single-cell RNA-sequencing atlas in a mouse model of diabetic kidney disease. These findings highlight the importance of leukocyte cell subtypes in diabetic kidney disease. |
The kidney-more than the sum of its cellular parts. The tubuloglomerular feedback is a prototypical example of cell-cell interactions adapting glomerular filtration rate. With the advent of single-cell sequencing techniques, spatial transcriptomics, and bioinformatical cell-cell interaction analyses, we are now able to much better decipher the complex physiology and pathophysiology of these crosstalks, and identify new biomarkers as well as novel treatment options. |
Treating crescentic glomerulonephritis by targeting macrophages. FROUNT, a C-C motif chemokine receptor 2 (CCR2)-interacted protein, which is strongly expressed in monocytes/macrophages, enhances macrophage infiltration through CCR2-mediated chemotaxis. In this issue of the journal, Toda et al reported that disulfiram, an inhibitor of FROUNT, attenuates GN by inhibition of the FROUNT-CCR2 interaction and macrophage migration and activation, suggesting a potential therapeutic role for crescentic GN. |
Urinary single-cell transcriptomics: a promising noninvasive method for assessing acute kidney injury. Urine samples from patients with AKI included tubular epithelial cells with injury-related dedifferentiation and adaptive phenotypes, which could reflect kidney tissue damage. Thus, urinary single-cell RNA sequencing would provide new insights into human AKI, leading to the identification of novel biomarkers and therapeutic targets. |
Vascular calcification in chronic kidney disease: contribution of ferroptosis? Apoptosis of vascular smooth muscle cells has long been known to play a major role in its pathogenesis, with apoptotic bodies derived from these cells acting as nucleating structures for calcium crystal formation and deposition. Ye et al now show in experimental models in vitro and in vivo that ferroptosis can also contribute to the development of vascular calcification in CKD. |
| Nephrol Dial Transplant |
Humoral response after the fourth dose of the SARS-CoV-2 vaccine in the CKD spectrum: a prespecified analysis of the SENCOVAC study. those with lower pre-booster antibody titers or KT recipients) derived the least benefit in terms of antibody titers. Admission for breakthrough COVID-19 was associated with low anti-Spike antibody titers. |
Preparing European Nephrology for the next pandemic: lessons from the ERACODA collaboration. Aligning different research initiatives, strengthening electronic health records, and involving experts in study design and data analysis will be important in our response to the next pandemic. The European Renal Association may take a leading role in aligning research initiatives via its engagement with other scientific societies, national registries, administrators, and researchers. |
RESET-PKD: A pilot trial on short-term ketogenic interventions in autosomal dominant polycystic kidney disease. RESET-PKD demonstrates that short-term KDIs potently induce ketogenesis and are feasible for ADPKD patients in daily life. While TLV quickly changed upon the onset of ketogenesis, changes in TKV may require longer-term interventions. |
Roxadustat (FG-4592) protects against ischemia-induced acute kidney injury via improving CD73 and decreasing AIM2 inflammasome activation. FG-4592 conveyed protection against AKI might be mediated by the induction of CD73 and the suppression of AIM2 inflammasome, which may provide a novel therapeutic method for the treatment of AKI. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Am J Kidney Dis |
| Clin J Am Soc Nephrol |
| Semin Nephrol |
Anesthesia and the renal sympathetic nervous system in perioperative AKI. Increased renal sympathetic nerve activity may impair renal excretory function and oxygenation and induce structural injury in ischemic AKI models and could therefore be a contributing factor to AKI in the perioperative setting. This review summarizes anesthetic agents' effects on the renal sympathetic nervous system that may be important in the pathogenesis of perioperative AKI. |
Ceramides and Acute Kidney Injury. This review examines the landscape of ceramide metabolism and regulation in the healthy and injured kidney. Furthermore, we discuss the body of literature regarding ceramides as therapeutic targets for AKI and consider potential mechanisms by which ceramides drive kidney pathogenesis. |
Filtering Down to Risks and Solutions: Risk Factors and Stratification After Pediatric Cardiac Surgery. CS-AKI appears to have different severity and duration phenotypes, and serum creatinine is limited in its ability to identify CS-AKI early and predict CS-AKI course. Treatment strategies are largely supportive, and efforts are ongoing to use biomarkers and clinical features to risk-stratify patients, which in turn may facilitate differential CS-AKI phenotyping and management with supportive care bundles, clinical decision support techniques, and modulation of modifiable risk factors. |
Hyperoxia and Acute Kidney Injury: A Tale of Oxygen and the Kidney. Overall, we found a significant need for both animal and clinical studies evaluating the role of hyperoxia in inducing kidney damage. Thus, we urge the research community to further investigate oxygen therapy and its impact on kidney health with the goal of optimizing oxygen therapy guidelines and improving patient care. |
Identifying Common Molecular Mechanisms in Experimental and Human Acute Kidney Injury. Since kidney biopsies are rarely performed in the acute injury phase in humans, most of our understanding of AKI pathophysiology is derived from preclinical AKI models. This raises the question of how well experimental models of AKI reflect the molecular and cellular mechanisms underlying human AKI? Here, we provide a brief overview of available AKI models, discuss their strengths and limitations, and consider important aspects of the AKI response in mice and humans, with a particular focus on the role of proximal tubule cells in adaptive and maladaptive repair. |
Systemic Effects of Tamm-Horsfall Protein in Kidney Disease. The generation of THP knockout mouse models has allowed the investigation of these phenomena and shown a prospective role for circulating THP in ischemia-reperfusion acute kidney injury as well as sepsis. Recent studies have suggested that THP is protective in ischemic injury owing to its inhibition of oxidative stress via the calcium channel transient receptor potential cation channel, subfamily M, member 2 t(TRPM2), and protection in sepsis is at least partially due to THP's promotion of macrophage function. |
The Significance of NAD+ Biosynthesis Alterations in Acute Kidney Injury. To enhance this understanding, we explore instances of NAD+ biosynthesis alterations outside the kidney in inflammation, pregnancy, and cancer. In doing so, we seek to highlight that the different NAD+ biosynthesis pathways are not interconvertible and propose that the way in which NAD+ is synthesized may be just as important as the NAD+ produced. |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Am J Kidney Dis |
| J Am Soc Nephrol |
| Kidney Int |
Letters to the editors and authors’ replies
| Am J Kidney Dis |
| Kidney Int |